
Human kidney cross section on scientific background
By loading a chelation drug into a nano-sized homing device, researchers at Clemson University have reversed in an animal model the deadliest effects of chronic kidney disease, which kills more people in the United States each year than breast or prostate cancer.
When kidneys stop working properly, calcium builds up in artery tissue, leading to heart disease. Although nearly half a million Americans receive kidney dialysis, heart disease is the leading cause of death for people with chronic kidney disease.
“The findings are very exciting scientifically, but also for the thousands of patients who could potentially benefit from this technology one day,” said Naren Vyavahare, the Hunter Endowed Chair and professor of bioengineering at Clemson and the principal investigator of the research.
Chelation, a method of removing metals such as iron and lead from the body, has been used experimentally for some people with heart disease. The therapy is not approved by the Food and Drug Administration, but the National Institutes of Health has sponsored two large-scale, multi-center studies using ethylene diamine tetra-acetic acid, or EDTA, as chelation therapy for people with heart disease.
In clinical studies, EDTA is included in an infusion that circulates through the body; it’s systemic and non-specific. This method of chelation has shown good results in improving heart function, especially in diabetic patients, Vyavahare said. But EDTA infusion therapy is arduous (it requires 40 infusions over a period of a year), and it can cause side effects, including a depletion of calcium from the blood and from bone.
In 2014, Vyavahare’s team proved a targeted approach is effective. In animals without kidney disease, they loaded nanoparticles with EDTA and special antibodies that recognize and latch onto damaged elastin to deliver the therapy directly to arterial sites damaged by calcification.
Now, in a paper published Feb. 22, 2019, in Scientific Reports, a Nature publication, Vyavahare’s team describes how they developed an animal model that mimics a human’s chronic kidney disease. Animals were treated either with EDTA infusions, like in the NIH human trials, or with EDTA enclosed in a nanoparticle coupled with an antibody that seeks out damaged elastin. In animals that received the targeted therapy, calcium buildup was destroyed, without causing side effects, better than with EDTA infusions alone. Moreover, the calcification did not come back up to four weeks after the last injection, even though other signs of chronic kidney disease were present.
“Dr. Vyavahare’s work is extremely important for those of us who believe that calcium is not just a passive indicator of coronary disease, but also an active participant,” said Gervasio Lamas, chairman of medicine and chief of cardiology at Mount Sinai Medical Center in Miami Beach, Florida. Lamas, principal investigator of the NIH-funded Trial to Assess Chelation Therapy 2, was not involved in the Clemson study.
“The potential with a targeted drug is enormous, and the methodology for targeting that Dr. Vyavahare has developed is unique,” Lamas said.
Vyavahare and his co-authors wrote that in a previous study they showed that polyphenols, when delivered with nanoparticles, “regenerate degraded aortic elastin. Thus, there is an exciting opportunity of dual nanoparticle therapy to first remove calcium deposits using EDTA and then restore medial elastin layers with (polyphenols).”
Vyavahare has been studying elastin degradation and damages caused by calcification for nearly 20 years. He’s director of the NIH-funded South Carolina Center of Biomaterials for Tissue Regeneration.
The nanoparticle delivery technology has been licensed by Elastrin Therapeutics, a startup company Vyavahare helped found. He serves as chief science officer of the company.
“With recent funding we received from NIH to carry out more studies on understanding how reversal of calcification works, and Elastrin Therapeutics Inc. licensing this technology from Clemson University, we believe we would be able to translate this approach for use in clinical trials within the next few years,” Vyavahare said.
Learn more: Cause of vascular disease in kidney failure reversed in animal model
The Latest on: Chronic kidney disease
[google_news title=”” keyword=”chronic kidney disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Chronic kidney disease
- Caring for Chronic Conditionson December 7, 2023 at 7:35 am
Zelkowitz explains, “One of our focuses as nephrologists is education both in terms of what chronic kidney disease is, how to slow down its progression and avoiding what we call ‘crash starts of ...
- Man felt 'fate calling' him to donate his kidney. He didn't expect what happened nexton December 7, 2023 at 7:29 am
"It was like fate was calling me." Hess, 31, was born with only one functioning kidney and has lived with chronic kidney disease for pretty much his entire life, he tells TODAY.com. As a kid, it ...
- Your Good Health: Salt substitute OK for most, unless you have kidney diseaseon December 7, 2023 at 6:30 am
Dear Dr. Roach: I have been using “lite salt,” which has 50% less sodium than regular table salt. Do you agree that this is OK?
- Kidney transplant: Three-year-old is smallest patienton December 6, 2023 at 4:11 pm
A three-year-old boy has become the smallest - and one of the youngest - recipients of a kidney transplant in Northern Ireland. Olly Cartmill was just 13kg (29lbs) when he underwent the life-saving ...
- 3 BRILLIANT MINUTES: Chronic Kidney Diseaseon December 6, 2023 at 4:02 pm
Conventional kidney health tests typically don’t show any problems until kidneys have lost 50% of their function.
- Statins Lower Risk of Dying in Older Adults with Chronic Kidney Diseaseon December 6, 2023 at 7:36 am
Researchers examined data on over 14,000 older adults with chronic kidney disease and no history of cardiovascular disease. Those taking a statin, a class of drugs used to lower cholesterol, had a ...
- Chronic Kidney Disease Warning Signs: What To Look Out Foron December 5, 2023 at 1:28 pm
Overview A condition characterized by a gradual loss of kidney function. Early stages can be asymptomatic. Disease progression occurs slowly over a period of time. Symptoms If you or someone you know ...
- Kidney diseases among children worry medicson December 4, 2023 at 8:53 pm
As of 2022, there were over 5,000 patients seeking dialysis services in various public and private health facilities in Kenya ...
- Link between gut dysbiosis and chronic diseases explored in new studyon December 4, 2023 at 4:00 pm
including cardiovascular disease, diabetes, chronic kidney disease, inflammatory bowel disease, and colorectal cancer. In this article, the authors have provided a detailed overview of the ecological ...
- Study challenges link between proton pump inhibitors and kidney disease riskon December 4, 2023 at 4:00 pm
A recent Scientific Reports study investigates whether the association between proton pump inhibitors (PPIs) and the use of histamine-2 receptor antagonists (H2RA) affects the risk of chronic kidney ...
via Bing News